For intravenous use Initial U.S. Approval: 2022
As specified in the prescribing information, ublituximab-xiiy injection is indicated for the treatment of Multiple Sclerosis disease. As per highlights Of prescribing information ublituximab-xiiy injection is CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults .
Facts about ublituximab-xiiy injection
Disease Indications: Multiple Sclerosis
Dosage Forms And Strengths: Injection: 150 mg/6 mL (25 mg/mL) in a single-dose via.
Manufacturer: TG Therapeutics
Medicine Approved By: Food and Drug Administration (FDA)
Briumvi (ublituximab-xiiy) was approved by the FDA in December 2022
- Full prescribing information [FDA]: Briumvi (ublituximab-xiiy) [PDF] TG Therapeutics, inc. December 2022.
- Press Release: TG Therapeutics announce the FDA approval for Briumvi (ublituximab-xiiy) TG Therapeutics, inc. December 2022
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “ublituximab-xiiy injection” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For ublituximab-xiiy injection
Approved accessible "ublituximab-xiiy injection"
Ublituximab, sold under the brand name Briumvi, is an immunomodulator used for the treatment of multiple sclerosis. It is a CD20-directed cytolytic monoclonal antibody. Ublituximab is indicated for the treatment of relapsing forms of multiple sclerosis. It was approved for medical use in the United States in December 2022.
How can 1 go about obtaining ublituximab-xiiy injection?
If ublituximab-xiiy injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Indian Pharma Network
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398